What is the effect of age on eculizumab pharmacokinetics?

ECULIZUMAB (ek yoo LYE zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots. Eculizumab is an oral medication designed to block the action of endothelin, a natural substance in the body that narrows blood vessels. By inhibiting ... Eculizumab is a humanized monoclonal antibody directed against C5 of the complement cascade and thereby inhibits the formation of C5a and C5b-9 membrane attack ... Eculizumab inhibits complement activation and EC damage and improves renal function. ... Eculizumab? What pathophysiological model apply to secondary HUS ... Apr 1, 2024 ... SOLIRIS is a medicine that affects your immune system and may lower the ability of your immune system to fight infections. SOLIRIS increases ... Mar 21, 2025 ... Eculizumab Biosimilars in PNH: Working Towards Broader Patient Access ... Eculizumab was the first drug approved for the treatment of complement- ... Oct 8, 2020 ... This guide is an educational resource to help patients and their caregivers understand health insurance coverage of SOLIRIS® (eculizumab). Learn ... May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... Jan 1, 2022 ... Soliris® (eculizumab) is unproven and not medically necessary for treatment of Shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS).